JonesTrading Taps Top Analyst Boris Peaker in Strategic Biotech Push

By Daniel Thomas

LOS ANGELES and NEW YORK – April 07, 2026 – JonesTrading Institutional Services LLC announced a significant enhancement to its research division today, appointing veteran analyst Boris Peaker, PhD, CFA, as Managing Director, Biotechnology Analyst. The move signals a deliberate strategy by the investment firm to deepen its expertise in the complex and high-stakes biotechnology sector.

Dr. Peaker, who brings over two decades of experience, will join JonesTrading's expanding Sector Research platform. His coverage will focus on some of the most dynamic areas of modern medicine: emerging technologies in oncology, immunology, and genetic medicines. This appointment is positioned as a key step in the firm's ambition to provide its institutional clients with more sophisticated, science-driven investment insights.

"This is an important step as we continue to broaden our healthcare research platform," said Alan Hill, CEO of Jones, in the official announcement. "Biotechnology remains a critical and rapidly evolving sector for our clients, and Boris' expertise will ensure we deliver the depth of insight needed to navigate it successfully."

A Strategic Play in a Competitive Field

JonesTrading, a firm founded in 1975 and known globally as a leader in block trading, is making a calculated move in a fiercely competitive landscape. The world of biotechnology research is dominated by bulge-bracket banks like Goldman Sachs and J.P. Morgan, alongside specialized powerhouses such as TD Cowen and Oppenheimer & Co.—firms where Dr. Peaker himself built a significant portion of his career.

By hiring a top-ranked analyst directly from this competitive pool, JonesTrading is not just adding a name; it is acquiring a reputation and a proven track record. Dr. Peaker spent more than a decade at TD Cowen, where he was instrumental in leading the firm's biotech coverage, and previously worked for three years at Oppenheimer. This background provides him with deep institutional knowledge that is critical for navigating equity markets.

This hire builds on JonesTrading's consistent efforts to bolster its research and investment banking teams. The firm has steadily added senior talent across its technology and healthcare verticals, including analysts like Soumit Roy, PhD, who heads healthcare research, and others specializing in SMID-cap biotech. Dr. Peaker's arrival complements this existing team, adding a senior voice focused specifically on the cutting-edge technologies poised to define the next decade of healthcare.

The Rise of the Hybrid Analyst

The appointment also underscores a crucial trend in modern financial analysis: the increasing value of the "hybrid analyst." Dr. Peaker embodies this model, pairing a PhD in Biophysics from Stanford University with the rigorous Chartered Financial Analyst (CFA) designation. This dual expertise is becoming indispensable for evaluating biotechnology companies, where a firm's value is intrinsically linked to complex clinical trial data, novel scientific mechanisms, and regulatory hurdles.

Analysts who can fluently speak the languages of both science and finance are uniquely positioned to offer differentiated insights. They can move beyond surface-level financial modeling to critically assess the viability of a drug's mechanism of action or the statistical significance of a clinical trial endpoint. This capability is precisely what JonesTrading sought in this hire.

Hans Vitzthum, Director of Research at Jones, highlighted this specific strength. "Boris is a highly regarded biotechnology analyst with a deep scientific foundation and a strong track record of delivering differentiated insights," Vitzthum noted. "His ability to interpret complex clinical data and identify key inflection points will meaningfully enhance our healthcare research platform."

For institutional investors, this level of analysis is paramount. In a sector known for its volatility—where stock prices can soar or plummet based on a single data readout—having an analyst who can accurately handicap the scientific risk is a significant competitive advantage.

Targeting Biotech's Next Frontiers

Dr. Peaker's mandate is sharply focused on oncology, immunology, and genetic medicines, three pillars of biotechnology that are experiencing explosive growth and innovation. These fields are no longer theoretical; they are producing transformative therapies that are reshaping patient care and creating substantial market opportunities.

• Oncology: Cancer treatment remains the largest therapeutic area in drug development. Innovation is moving rapidly towards precision medicine, next-generation immuno-oncology platforms like CAR-T cells and bispecific antibodies, and novel modalities like radiopharmaceuticals. Investment in this space continues to climb as the global cancer burden grows.

• Immunology: Driven by a deeper understanding of the immune system, this field is producing breakthroughs not only in cancer but also in treating a wide range of autoimmune diseases. The success of monoclonal antibodies has paved the way for more sophisticated approaches to either activate or suppress immune responses with greater precision.

• Genetic Medicines: Perhaps the most revolutionary of the three, genetic medicine promises to move from treatment to cure. The 2023 approval of the first CRISPR-based therapy, Casgevy, was a landmark moment, validating a technology that can directly edit DNA to correct disease-causing mutations. With mRNA platforms, RNAi therapeutics, and next-generation gene-editing tools in development, this area is poised for exponential growth.

By dedicating a senior analyst to these specific frontiers, JonesTrading is positioning itself and its clients to capitalize on long-term secular growth trends. The firm is betting that success in 21st-century investing will require not just broad market coverage, but deep, specialized knowledge of the technologies that are fundamentally changing the world. Dr. Peaker's appointment is a clear and decisive step in that direction, equipping the firm with the expertise to navigate the scientific and financial complexities of biotech's most promising fields.